Navigation Links
Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
Date:5/1/2012

SAN DIEGO, May 1, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA), has exercised its option associated with the existing Pfenex contractual relationship begun in July, 2010. This extends the contract supporting the development of a robust Pfēnex Expression Technology™ based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax. Pursuant to the contract, Pfenex will continue to develop an rPA-based anthrax vaccine from rPA produced in Pseudomonas fluorescens.  During the contract's base period, Pfenex demonstrated that a strongly immunogenic, stable and protective form of rPA could be expressed and recovered from the highly efficient fermentation of a strain of P. fluorescens engineered to produce rPA.

"We are pleased with the results and progress provided by Pfenex's recombinant platform technology to the production of a next generation anthrax vaccine," stated Bertrand C. Liang, Chief Executive Officer. "The exercise of this option by BARDA enables Pfenex and BARDA to continue our successful partnership sharing a common objective to develop an anthrax vaccine with a process capable of achieving the goals of the Strategic National Stockpile for the U.S. Government, including production, shelf life, and administration improvements."

About Pfenex Inc.

Pfenex Inc. is a protein production company leveraging the unique and powerful Pfenex Expression Technology™ platform based on the microorganism, Pseudomonas fluorescens, for the production of research proteins, reagent proteins, biosimilars and innovator biopharmaceuticals. For more information please visit www.pfenex.com


'/>"/>
SOURCE Pfenex Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. OptiScan Biomedical Presents Study Results Demonstrating OptiScanners Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients
2. Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies
3. What Recession? How Biomedical Device Companies Thrived in a Bad Economy
4. Crux Biomedicals IVC Filter Receives CE Mark Approval
5. HealthTech Capital Leads Series A2 With Over $300,000 Investment in Cadence Biomedical
6. Survey of Biomedical Industry CEOs Finds Lack of Investment and Regulatory Environment Threaten Future Growth and Innovation
7. Pepex Biomedical Signs Seven Year Deal to Manufacture "Trio™"
8. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
9. Dr. Paul Janssen Award for Biomedical Research Issues Call for Nominations
10. U.S. Biomedical Leaders Present Leaders on Capitol Hill with New National Strategy for Innovation
11. Saladax Biomedical, Inc. Names Edward Chu, M.D., Chair of the Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... Market Analysis 2016 - Forecast to 2022" report to ... report contains up to date financial data derived from varied ... major trends with potential impact on the market during the ... segmentation which comprises of sub markets, regional and country level ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):